Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type. 
Cervical adenocarcinomas most frequently harbor alterations in TP53, KRAS, PIK3CA, ARID1A, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in cervical adenocarcinoma .
There are 28 clinical trials for cervical adenocarcinoma, of which 26 are open and 2 are completed or closed. Of the trials that contain cervical adenocarcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 10 are phase 2 (10 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (7 open).
PD-L1, CDKN2A, and HPV are the most frequent gene inclusion criteria for cervical adenocarcinoma clinical trials .
Pembrolizumab, bevacizumab, and paclitaxel are the most common interventions in cervical adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.